Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 15, 2005. The report is a notification of changes in directors' interests in the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is limited to reporting specific share transactions and does not contain financial statements.
Material Changes
The only material change reported is a transaction involving the GlaxoSmithKline Employee Trust ("the GSK Trust"). On April 14, 2005, Abacus (GSK) Trustees Limited transferred 8,934 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risks, contingencies, or unusual items. It strictly details the share transfer and notes that three directors (Dr J-P Garnier, Dr T Yamada, and Mr J S Heslop) are interested in the shares held in the GSK Trust as potential beneficiaries alongside other employees.
Investor Verification Points
- Verify the impact of the 8,934 share transfer on the total outstanding share count.
- Confirm the specific holdings of directors Dr J-P Garnier, Dr T Yamada, and Mr J S Heslop through the GSK Trust.
- Review the terms of the SmithKline Beecham Employee Share Option Plan 1991 to understand the vesting or exercise conditions for the transferred shares.